Baillie Gifford WW Health Innovation Fund

This is a new strategy but leans into the wider Baillie Gifford Group and aims to take advantage of the positive impact of biology to health and the health care industry. They see that the changes happening are a biological revolution that push our understanding of biology, with sequencing the genome being the principal driver behind this.

The pace of change is getting faster every day and they want to invest in companies that are transforming the healthcare industry. They invest across five buckets: understanding of diseases, diagnostics, treatment, prevention, and operational efficiency….read more

Fund Facts Morningstar


Please note... is not regulated by the FCA. The information is purely a guide and it is the responsibility of the investor to carry out their own research before making any final decisions. We will ensure that the information is as accurate as possible but we cannot be held accountable for any errors or omissions. No products are sold on this site, nor do we endorse any particular product or investment.

Where there are links to third party sites this is not an endorsement of that site, and we cannot be held responsible for the accuracy of the information on that site.

Where there is reference to performance you should note that past performance is purely a guide and investments can fall as well as rise.

The information on the site belongs to and cannot be replicated or copied without our permission.